
Image not found or type unknown

40


年历史的中东和北非制药

Image not found or type unknown



PRINTED ON: *October 30, 2026, 4:58 AM (EST)* **PUBLISHED ON:** *October 30, 2026, 3:58 AM (EST)* **UPDATED ON:** *October 30, 2026, 3:58 AM (EST)*

MERGERSCORP



40

这家制药公司于约 40 年前在约旦安曼成立。 它拥有 70 多项专利，是地区创新标杆。

这种创新的直接结果是，通过将成熟的技术平台分拆成拥有独立管理和资源的子公司，在传统的非专利药品行业之外实现了业务多元化。

纵向

1.核心品牌非专利药品业务。

2.通过子公司获得天然产品。

3.通过子公司开展生物技术诊断。

4.通过子公司开发新型辅料和给药系统。

产品

TARGET PRICE

$45,000,000

GROSS REVENUE

$37,000,000

EBITDA

$6,279,944

BUSINESS TYPE

制药

COUNTRY

约旦

BUSINESS ID

L#20230509

产品涵盖广泛的治疗类别，包括心血管、胃肠道、中枢神经系统、抗感染、内分泌、肌肉骨骼、呼吸系统、妇产科和泌尿系统以及免疫系统。

制药业务

它提供 200 多种药品，满足消费者和医疗保健专业人员的需求。
这些产品包括片剂、胶囊、栓剂、糖浆和混悬液，均按照《药品生产质量管理规范》（GMP）生产。 由于产品 “质量
“高，该公司具有竞争优势，成为领先的制药公司之一。

天然产品

该公司在中东地区享有盛誉，是利用标准化药用植物提取物开发和生产植物和草药医疗产品的最佳企业之一，提供 50 多种天然和草药创新产品，业务遍及全球 20 多个国家。

生物技术

它是一家专有生物技术保健产品的开发商和生产商，专门从事生产。

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE
AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM